Multiple sclerosis

Ekso Bionics Reports Fourth Quarter and Year End 2022 Results

Retrieved on: 
Tuesday, March 28, 2023

Revenue in the fourth quarter of 2022 included approximately $3.5 million in EksoHealth revenue and approximately $0.1 million in EksoWorks revenue.

Key Points: 
  • Revenue in the fourth quarter of 2022 included approximately $3.5 million in EksoHealth revenue and approximately $0.1 million in EksoWorks revenue.
  • The Company booked a total of 27 EksoHealth devices in the fourth quarter of 2022.
  • Sales and marketing expenses for the quarter ended December 31, 2022 were $1.9 million, compared to $2.0 million for the same period in 2021.
  • Research and development expenses for the quarter ended December 31, 2022 were $0.9 million, compared to $0.8 million for the same period in 2021.

Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer

Retrieved on: 
Monday, March 27, 2023

DANBURY, Conn., March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has joined the company as Executive Vice President, Chief Operating Officer, effective today.

Key Points: 
  • DANBURY, Conn., March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has joined the company as Executive Vice President, Chief Operating Officer, effective today.
  • Sabella will report directly to Michael Castagna, PharmD, Chief Executive Officer, and serve on the company’s executive leadership team.
  • “Lauren is an inspirational leader, and we are delighted to welcome her to MannKind at a pivotal time,” said Dr. Castagna.
  • Prior to that role, Sabella was Acorda’s Chief Commercial Officer and launched their flagship product Ampyra® for multiple sclerosis whose peak sales exceeded half a billion dollars.

Titan Partners Group Announces Addition of Dr. David Sans as Head of Healthcare

Retrieved on: 
Monday, March 27, 2023

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Titan Partners Group LLC, a division of American Capital Partners, LLC (“Titan Partners”), announces today that Dr. David Sans has joined the firm as head of healthcare.

Key Points: 
  • NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Titan Partners Group LLC, a division of American Capital Partners, LLC (“Titan Partners”), announces today that Dr. David Sans has joined the firm as head of healthcare.
  • Dr. Sans will lead the healthcare team, which covers companies in the biopharmaceuticals, diagnostics, medtech and specialty pharmaceuticals sectors.
  • “We are excited to bring in David Sans to join Titan Partners and lead our healthcare practice as we continue to expand our footprint and capacity in this sector,” commented Michael Sands, Titan Partners co-founder and partner.
  • Titan Partners is committed to building out a leading healthcare division.

Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests

Retrieved on: 
Tuesday, March 28, 2023

Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems.

Key Points: 
  • Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems.
  • These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light (NfL) in human Cerebrospinal fluid (CSF) and plasma/serum, respectively, within just 35 minutes.
  • This standardized immunoassay system family is widely available and used in routine labs active in the field of neurological diseases with its current assay menu.
  • The LUMIPULSE G platform meets the necessary throughput, quality, and regulatory requirements to support possible future routine use of NfL in addition to the existing portfolio.

The Department of Health - Abu Dhabi Recognises Abu Dhabi Stem Cells Center (ADSCC) as a Centre of Excellence in Hematopoietic Stem Cell Transplantation

Retrieved on: 
Tuesday, March 28, 2023

Dr. Noura Al Ghaithi, Acting Undersecretary of the Department of Health - Abu Dhabi, Farhan Malik, Managing director and CEO Of PureHealth Group, Dr. Yendry Ventura, CEO of the Abu Dhabi Stem Cells Center (ADSCC), and Dr. Fatima Alkaabi, Executive Director of the Bone Marrow Transplant Program at the Abu Dhabi Stem Cells Center (ADSCC).

Key Points: 
  • Dr. Noura Al Ghaithi, Acting Undersecretary of the Department of Health - Abu Dhabi, Farhan Malik, Managing director and CEO Of PureHealth Group, Dr. Yendry Ventura, CEO of the Abu Dhabi Stem Cells Center (ADSCC), and Dr. Fatima Alkaabi, Executive Director of the Bone Marrow Transplant Program at the Abu Dhabi Stem Cells Center (ADSCC).
  • The Department of Health – Abu Dhabi outlines six key indicators that are taken into consideration when evaluating whether the healthcare facility can be recognised as a Centre of Excellence.
  • Following the announcement, Shaista Asif Group Chief Operating Officer of PureHealth said: "The selection of the Abu Dhabi Stem Cell Center as a center of excellence in Hematopoietic Stem Cell Transplantation is a prestigious honor.
  • The Abu Dhabi Bone Marrow Transplant Programme provides treatment to all patients through the Abu Dhabi Stem Cells Center as well as Yas Clinic Hospital Khalifa City.

The Department of Health - Abu Dhabi Recognises Abu Dhabi Stem Cells Center (ADSCC) as a Centre of Excellence in Hematopoietic Stem Cell Transplantation

Retrieved on: 
Tuesday, March 28, 2023

Dr. Noura Al Ghaithi, Acting Undersecretary of the Department of Health - Abu Dhabi, Farhan Malik, Managing director and CEO Of PureHealth Group, Dr. Yendry Ventura, CEO of the Abu Dhabi Stem Cells Center (ADSCC), and Dr. Fatima Alkaabi, Executive Director of the Bone Marrow Transplant Program at the Abu Dhabi Stem Cells Center (ADSCC).

Key Points: 
  • Dr. Noura Al Ghaithi, Acting Undersecretary of the Department of Health - Abu Dhabi, Farhan Malik, Managing director and CEO Of PureHealth Group, Dr. Yendry Ventura, CEO of the Abu Dhabi Stem Cells Center (ADSCC), and Dr. Fatima Alkaabi, Executive Director of the Bone Marrow Transplant Program at the Abu Dhabi Stem Cells Center (ADSCC).
  • The Department of Health – Abu Dhabi outlines six key indicators that are taken into consideration when evaluating whether the healthcare facility can be recognised as a Centre of Excellence.
  • Following the announcement, Shaista Asif Group Chief Operating Officer of PureHealth said: "The selection of the Abu Dhabi Stem Cell Center as a center of excellence in Hematopoietic Stem Cell Transplantation is a prestigious honor.
  • The Abu Dhabi Bone Marrow Transplant Programme provides treatment to all patients through the Abu Dhabi Stem Cells Center as well as Yas Clinic Hospital Khalifa City.

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

Retrieved on: 
Wednesday, March 22, 2023

BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2022, and provided recent business highlights. The Company also today announced that founding chief executive officer (CEO), Axel Bolte, MSc, MBA, will retire from his current role and that Douglas A. Treco, Ph.D., chairman of the Company’s board of directors (Board), will succeed Mr. Bolte as the CEO of the Company, effective April 1, 2023.

Key Points: 
  • BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2022, and provided recent business highlights.
  • I look forward to continuing to benefit from his experience as a senior advisor and Board member,” said Dr. Treco.
  • Axel Bolte, MSc, MBA, the Company’s founding CEO will retire and continue to work with Inozyme as a senior advisor and serve on the Board.
  • Dr. Winton most recently served as senior vice president and head of the Multiple Sclerosis franchise for Biogen’s US organization.

FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder

Retrieved on: 
Wednesday, March 22, 2023

Hundreds of millions of people globally need new, safer, accessible and more effective options to redefine the front-line approach by getting to the root of the disorder and how it is currently treated.

Key Points: 
  • Hundreds of millions of people globally need new, safer, accessible and more effective options to redefine the front-line approach by getting to the root of the disorder and how it is currently treated.
  • MDD can be a chronic condition with multiple periods of regression and relapse over a lifetime.
  • Different types of MDD include Seasonal Affective Disorder (SAD), Postpartum depression, psychotic depression, melancholic depression, and catatonic depression.
  • According to Allied Market Research, the global antidepressant drugs market size was valued at $15.65 billion in 2020 and is projected to reach $21.0 billion by 2030.2

Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

Retrieved on: 
Wednesday, March 22, 2023

Brain penetrant inhibitors of TYK2/JAK1 have the potential to bring this validated immune target to brain disorders.

Key Points: 
  • Brain penetrant inhibitors of TYK2/JAK1 have the potential to bring this validated immune target to brain disorders.
  • There are currently no brain penetrant, selective, dual TYK2/JAK1 inhibitors approved for brain disorders.
  • We have delivered what we believe is a best-in-class dual TYK2/JAK1 molecule and the team at Biohaven has the clinical development expertise to explore its utility in brain disorders.
  • We are excited to work with Chris and the team at Highlightll to advance this novel and highly differentiated dual TYK2/JAK1 inhibitor in the treatment of brain disorders."

Local Non-profit Announces The Ultimate Charity Climb, "ATL on STAIRoids"

Retrieved on: 
Tuesday, March 21, 2023

The exciting, interactive charity fundraising event is open to everyone eight years and older.

Key Points: 
  • The exciting, interactive charity fundraising event is open to everyone eight years and older.
  • This climb event is dedicated to everyone touched by chronic neurological diseases like Multiple Sclerosis (MS), Parkinson's, Epilepsy, and Alzheimer's.
  • Dr. Jeffrey English, Medical Director at Atlanta Neuroscience Institute (ANI), says, "There are added benefits to an event like this.
  • Up to one billion people are living with a neurological disorder — 100 million of which live in the United States.